Article
Histone Deacetylase Inhibitors and Diabetic Kidney Disease
5 Sept 2018
Abstract excerpt
Despite recent clinical trial advances and improvements in clinical care, kidney disease due to diabetes remains the most common cause of chronic kidney failure worldwide. In the search for new treatments, recent attentions have turned to drug repurposing opportunities, including study of the histone deacetylase (HDAC) inhibitor class of agents. HDACs are a group of enzymes that remove functional acetyl groups...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
